BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38776875)

  • 1. Integrated functional genomic screening to bypass TKI resistance in chronic myeloid leukemia.
    Beinortas T; Huntly BJP
    Cell Rep Med; 2024 May; 5(5):101565. PubMed ID: 38776875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
    Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
    J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia.
    Sun J; Hu R; Han M; Tan Y; Xie M; Gao S; Hu JF
    Int J Biol Sci; 2024; 20(1):175-181. PubMed ID: 38164178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FAM167A is a key molecule to induce BCR-ABL-independent TKI resistance in CML via noncanonical NF-κB signaling activation.
    Yang T; Sim KY; Ko GH; Ahn JS; Kim HJ; Park SG
    J Exp Clin Cancer Res; 2022 Mar; 41(1):82. PubMed ID: 35241148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
    Adnan Awad S; Dufva O; Klievink J; Karjalainen E; Ianevski A; Pietarinen P; Kim D; Potdar S; Wolf M; Lotfi K; Aittokallio T; Wennerberg K; Porkka K; Mustjoki S
    Cell Rep Med; 2024 May; 5(5):101521. PubMed ID: 38653245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
    Ferri C; Bianchini M; Bengió R; Larripa I
    Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
    Inoue A; Kobayashi CI; Shinohara H; Miyamoto K; Yamauchi N; Yuda J; Akao Y; Minami Y
    Int J Hematol; 2018 Oct; 108(4):365-370. PubMed ID: 30155588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Mechanisms of Tyrosine Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.
    Kaehler M; Cascorbi I
    Handb Exp Pharmacol; 2023; 280():65-83. PubMed ID: 36882601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
    Bolton-Gillespie E; Schemionek M; Klein HU; Flis S; Hoser G; Lange T; Nieborowska-Skorska M; Maier J; Kerstiens L; Koptyra M; Müller MC; Modi H; Stoklosa T; Seferynska I; Bhatia R; Holyoake TL; Koschmieder S; Skorski T
    Blood; 2013 May; 121(20):4175-83. PubMed ID: 23543457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
    PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia.
    Huang R; Kang Q; Liu H; Li Y
    Curr Cancer Drug Targets; 2016; 16(4):323-45. PubMed ID: 26391311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of autophagy: a new strategy to enhance sensitivity of chronic myeloid leukemia stem cells to tyrosine kinase inhibitors.
    Calabretta B; Salomoni P
    Leuk Lymphoma; 2011 Feb; 52 Suppl 1(Suppl 1):54-9. PubMed ID: 21250825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents.
    Talati C; Pinilla-Ibarz J
    Curr Opin Hematol; 2018 Mar; 25(2):154-161. PubMed ID: 29266016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
    Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
    Elias MH; Baba AA; Azlan H; Rosline H; Sim GA; Padmini M; Fadilah SA; Ankathil R
    Leuk Res; 2014 Apr; 38(4):454-9. PubMed ID: 24456693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Resistance to Tyrosine Kinase Inhibitors.
    Yaghmaie M; Yeung CC
    Curr Hematol Malig Rep; 2019 Oct; 14(5):395-404. PubMed ID: 31463864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options.
    Meenakshi Sundaram DN; Jiang X; Brandwein JM; Valencia-Serna J; Remant KC; Uludağ H
    Drug Discov Today; 2019 Jul; 24(7):1355-1369. PubMed ID: 31102734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.